Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yayoi Tada

Showing results (51-60 of 251) with videos related to

Pageof 26
Sort By:
Clinical Immunology (Orlando, Fla.)|January 10, 2015
Deficiency of both L-selectin and ICAM-1 exacerbates imiquimod-induced psoriasis-like skin inflammation through increased infiltration of antigen presenting cellsAya Mitsui, Yayoi Tada, Sayaka Shibata, et al.
Journal of Dermatological Science|April 23, 2021
Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodesIori Okura, Masahiro Kamata, Yoshihide Asano, et al.
Biochemical and Biophysical Research Communications|May 11, 2005
Signaling through CD40 ligand decreases CD80 expression on murine Langerhans cells and enhances IL-12 p40 productionMakoto Sugaya, Koichiro Nakamura, Akihiko Asahina, et al.
Journal of Medical Economics|June 5, 2025
A cost-effectiveness analysis of deucravacitinib <i>vs.</i> apremilast in moderate-to-severe psoriasis patients in JapanGijs van de Wetering, Hyunchung Kim, David Roberts, et al.
The Journal of Dermatology|May 15, 2024
Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance studyYayoi Tada, Yukako Sugiura, Manami Kamishima, et al.
The Journal of Dermatology|March 29, 2025
Real-world safety and effectiveness of guselkumab in patients with psoriasis: A post-marketing surveillance study through up to week 52 in JapanYayoi Tada, Yukako Sugiura, Manami Kamishima, et al.
Cytokine|May 28, 2004
Differential effects of LPS and TGF-beta on the production of IL-6 and IL-12 by Langerhans cells, splenic dendritic cells, and macrophagesYayoi Tada, Akihiko Asahina, Hideki Fujita, et al.
Clinical Rheumatology|February 3, 2012
Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisisKoichi Yanaba, Yoshihide Asano, Yayoi Tada, et al.
Journal of Dermatological Science|November 21, 2013
TLR4, rather than TLR2, regulates wound healing through TGF-β and CCL5 expressionHiraku Suga, Makoto Sugaya, Hideki Fujita, et al.
The Journal of Investigative Dermatology|June 25, 2010
Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania majorKatharina Kronenberg, Sven Brosch, Florian Butsch, et al.
Pageof 26

Showing results (51-60 of 251) with videos related to

Sort By:
Pageof 26
Clinical Immunology (Orlando, Fla.)|January 10, 2015
Deficiency of both L-selectin and ICAM-1 exacerbates imiquimod-induced psoriasis-like skin inflammation through increased infiltration of antigen presenting cellsAya Mitsui, Yayoi Tada, Sayaka Shibata, et al.
Journal of Dermatological Science|April 23, 2021
Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodesIori Okura, Masahiro Kamata, Yoshihide Asano, et al.
Biochemical and Biophysical Research Communications|May 11, 2005
Signaling through CD40 ligand decreases CD80 expression on murine Langerhans cells and enhances IL-12 p40 productionMakoto Sugaya, Koichiro Nakamura, Akihiko Asahina, et al.
Journal of Medical Economics|June 5, 2025
A cost-effectiveness analysis of deucravacitinib <i>vs.</i> apremilast in moderate-to-severe psoriasis patients in JapanGijs van de Wetering, Hyunchung Kim, David Roberts, et al.
The Journal of Dermatology|May 15, 2024
Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance studyYayoi Tada, Yukako Sugiura, Manami Kamishima, et al.
The Journal of Dermatology|March 29, 2025
Real-world safety and effectiveness of guselkumab in patients with psoriasis: A post-marketing surveillance study through up to week 52 in JapanYayoi Tada, Yukako Sugiura, Manami Kamishima, et al.
Cytokine|May 28, 2004
Differential effects of LPS and TGF-beta on the production of IL-6 and IL-12 by Langerhans cells, splenic dendritic cells, and macrophagesYayoi Tada, Akihiko Asahina, Hideki Fujita, et al.
Clinical Rheumatology|February 3, 2012
Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisisKoichi Yanaba, Yoshihide Asano, Yayoi Tada, et al.
Journal of Dermatological Science|November 21, 2013
TLR4, rather than TLR2, regulates wound healing through TGF-β and CCL5 expressionHiraku Suga, Makoto Sugaya, Hideki Fujita, et al.
The Journal of Investigative Dermatology|June 25, 2010
Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania majorKatharina Kronenberg, Sven Brosch, Florian Butsch, et al.
Pageof 26